InvestSMART

Patrys Limited (ASX:PAB)

ALERT: Price-sensitive ASX Announcement for PAB
Current share price for PAB : $0.033 -0.007 (-17.50%)+
Announcement
Release
13 Jul 2026 8:22AM
Price at Release
$0.040
Full Release
download
Summary
Patrys Limited announced a strategic agreement with Yale University, allowing Patrys to secure a 50% revenue share in the commercialisation of the deoxymab intellectual property portfolio. This move significantly reduces Patrys' future capital requirements while maintaining shareholder exposure to potential future success of the deoxymab platform. The transaction involves assigning deoxymab IP to the University, which will manage future development, paving the way for a new start-up entity to further the project's commercialisation. This agreement is considered a strategic milestone to advance the deoxymab platform under a university-supported framework that can access specialist expertise and external funding.
Key Points
  • Patrys secures 50% revenue share in deoxymab IP commercialisation.
  • Agreement with Yale University to support deoxymab development.
  • University responsible for most future research and development costs.
  • Patrys retains significant long-term economic exposure to future success.
  • New start-up entity to be formed for further deoxymab development.
  • Strategic milestone reducing Patrys' capital requirements.
  • University-backed commercialisation framework to enhance project potential.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.